Gilead Plans $8-M Investment to Expand Operations in IrelandBy
Gilead Sciences has announced plans to invest EUR 7 million ($8 million) to expand its operations in Ireland with the opening a new base in Dublin, the establishment a pediatric center of excellence in Ireland, and the addition of 140 new jobs.
The company is currently in the process of selecting a location for its new Dublin office, where the majority of the new positions will be based with the remaining roles located at Gilead’s existing Cork, Ireland facilities. The company has started the recruitment process and expects to fill 80 of the positions over the coming 12 months (as reported on July 8, 2020), with the remainder hired by early 2022. The company is adding positions at all levels in multiple departments, including clinical development, process development and analytical operations, legal, human resources, supply chain, information technology, facilities and engineering, and financial shared services.
Gilead’s sites in Ireland include a drug-product manufacturing and packing facility in Carrigtwohill, County Cork that manufactures and packages 22 Gilead drug products, including HIV and hepatitis C solid oral products, which represent 25% of Gilead’s total solid oral drug production. The company also has a financial shared services center in Little Island, County Cork, which supports Gilead affiliates in Europe, the Middle East, Asia, and South America, and a distribution center in Dublin that distributes to 90 markets globally.
To date, Gilead has invested more than EUR 225 million ($257 million) in Ireland, according to information from IDA Ireland, an economic development agency in Ireland. The company employs 370 full-time employees in Ireland and an additional 119 contingent workers.
Source: IDA Ireland